259 results
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
that these programs are core to its values, will create a working environment where its employees will flourish and achieve its corporate objectives … the competitive market environment and reviews on a yearly basis a benchmarking analysis using compensation information filed by comparable publicly listed
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
consolidated interim financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
of global environment and global economic conditions;
the impact of COVID-19 on participant enrollment;
the risks of delays and inability to complete
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
and prospects, including to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment … environment due to consolidation, achievement of forecasted burn rate, achievement of forecasted preclinical study and clinical trial milestones, reliance
6-K
EX-99.1
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
, including impact to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment, supply chain … impacts, fluctuations in costs, changes to the competitive environment, reliance on third parties to conduct preclinical studies and clinical trials
6-K
EX-99.2
q2djrow1 den1efuedl
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.1
jm37thob5t d5
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.1
a7zpd
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.2
xvtyjomm1sllh3ni5m
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
6-K
EX-99.1
6lhxt
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
7akf415c k241a
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
4v48960 7ng180ep0
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
nkist93g2fd9jqkj
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
aruu2d6p0wc
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
t3cwyn nn6jt
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
57il3uqf j4
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
oui9 ae6c67wa4ms
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
zjhinz8j 950e679en
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
6-K
EX-99.1
4cbvuh3yj1t oymc
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
5q5j 2l69qwwrr
26 Aug 22
Registration of securities (Canada)
4:48pm